New York Life Investment Management LLC Has $6.11 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

New York Life Investment Management LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 0.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 286,251 shares of the company’s stock after acquiring an additional 665 shares during the period. New York Life Investment Management LLC’s holdings in Kenvue were worth $6,111,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of KVUE. Grove Bank & Trust grew its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at $35,000. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc grew its holdings in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 1.9 %

Shares of NYSE:KVUE opened at $23.58 on Friday. The company’s 50-day moving average price is $21.46 and its two-hundred day moving average price is $22.26. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The stock has a market capitalization of $45.07 billion, a PE ratio of 44.49, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.48%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KVUE. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Piper Sandler boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Citigroup decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Finally, Canaccord Genuity Group reduced their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.